Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YN9Y
|
|||
| Drug Name |
MB-101
|
|||
| Indication | Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 1 | [1], [2], [3] | |
| Company |
Mustang Bio New York, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 13 receptor alpha-2 (IL13RA2) | Target Info | Immunomodulator | [2] |
| KEGG Pathway | Jak-STAT signaling pathway | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.